Pál Berzsenyi
About
In The Last Decade
Pál Berzsenyi
18 papers receiving 426 citations
Peers
Comparison fields: 5 of 60
- Cellular and Molecular Neuroscience 317
- Molecular Biology 224
- Pharmacology 59
- Physiology 56
- Psychiatry and Mental health 56
Countries citing papers authored by Pál Berzsenyi
This map shows the geographic impact of Pál Berzsenyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pál Berzsenyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pál Berzsenyi more than expected).
Fields of papers citing papers by Pál Berzsenyi
This network shows the impact of papers produced by Pál Berzsenyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pál Berzsenyi. The network helps show where Pál Berzsenyi may publish in the future.
Co-authorship network of co-authors of Pál Berzsenyi
This figure shows the co-authorship network connecting the top 25 collaborators of Pál Berzsenyi. A scholar is included among the top collaborators of Pál Berzsenyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pál Berzsenyi. Pál Berzsenyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 28 | |
| 3 | 35 | |
| 4 | 4 | |
| 5 | 27 | |
| 6 | Omeprazole and talampanel as two examples of retrometabolic drug design. | 2 |
| 7 | 9 | |
| 8 | 52 | |
| 9 | 11 | |
| 10 | 1 | |
| 11 | 53 | |
| 12 | Reflex inhibitory action of a non-NMDA type excitatory amino acid antagonist, GYKI 52466. | 14 |
| 13 | 6 | |
| 14 | 115 | |
| 15 | 28 | |
| 16 | A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity. | 17 |
| 17 | 10 | |
| 18 | Neuropharmacology of a new psychotropic 2,3-benzodiazepine. | 13 |
| 19 | 22 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.